Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

5.450 +0.150 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 Next >
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
From Compass Pathways plc
Via Business Wire
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Compass Pathways appoints Teri Loxam as Chief Financial Officer
From Compass Pathways
Via GlobeNewswire
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression 
From Compass Pathways
Via GlobeNewswire
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
COMPASS Pathways announces CFO transition
From COMPASS Pathways
Via GlobeNewswire
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Exposures Product Safety
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Exposures Product Safety
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
By Rachael Green, Benzinga 
Via TheNewswire.com
Exposures Product Safety
Largest Phase 3 Clinical Trial on Psilocybin Gets Underway
Via Investor Brand Network
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
American Medical Association to Issue First New Code for Psychedelic Therapies
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved 
From COMPASS Pathways
Via GlobeNewswire
Compass Pathways Plc (NASDAQ: CMPS) Highlighted for Surprising Price Action
Via Investor Brand Network
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City... 
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one... 
Via FinancialNewsMedia
Psychedelics May Make People Less Afraid of Death
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change... 
Via FinancialNewsMedia
Topics Supply Chain
Exposures Supply Chain
Compass Pathways to Begin New Phase 2 Psychedelic Trial for Anorexia
Via Investor Brand Network
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam... 
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Appeal Board Upholds Compass Pathways’ Patent on Synthetic Psilocybin Formulation
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
World’s Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a... 
Via FinancialNewsMedia
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.